Your search has found 459 articles in the database for the term 'Quality of Life of Person With Dementia'
Click
here to filter this large number of results.
Effects of multicomponent exercise on spatial-temporal gait parameters among the elderly with amnestic mild cognitive impairment (aMCI): preliminary results from a randomized controlled trial (RCT)
Doi, Takehiko,
Makizako, Hyuma,
Shimada, Hiroyuki,
Yoshida, Daisuke,
Tsutsumimoto, Kota,
Sawa, Ryuichi,
Misu, Shogo,
Suzuki, Takao
Exercise training has been shown to increase physical function in the elderly. However, the effects of exercise on elderly individuals with amnestic aMCI are unclear. The aim of...
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease
Sabbagh, Marwan N.,
Agro, Albert,
Bell, Joanne,
Aisen, Paul S,
Schweizer, Edward,
Galasko, Douglas
...Objective: To evaluate the safety and tolerability of PF-04494700, an oral inhibitor of receptor for advanced glycation end products, in patients with mild-to-moderate dementia of the Alzheimer type.; Methods:...
Plasma free choline, betaine and cognitive performance: the Hordaland Health Study
Nurk, Eha,
Refsum, Helga,
Bjelland, Ingvar,
Drevon, Christian A.,
Tell, Grethe S.,
Ueland, Per M.,
Vollset, Stein E.,
Engedal, Knut,
Nygaard, Harald A.,
Smith, David A.
Choline and betaine are nutrients involved in one-carbon metabolism. Choline is essential for neurodevelopment and brain function. We studied the associations between cognitive function and plasma concentrations of...
Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: A randomized, placebo-controlled trial
Rosenberg, Paul B.,
Lanctôt, Krista L.,
Drye, Lea T.,
Herrmann, Nathan,
Scherer, Roberta W.,
Bachman, David L.,
Mintzer, Jacobo E.
...Objective: In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer’s disease. We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET). Method: Six-week, randomized,...
Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort
Soto, Maria E.,
Abellan van Kan, Gabor,
Nourhashemi, Fati,
Gillette-Guyonnet, Sophie,
Cesari, Matteo,
Cantet, Christelle,
Rolland, Yves,
Vellas, Bruno
Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive...
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
...from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment)....